IL2 and neoplasm: In multicenter phase I/II clinical trial, high-risk tumor patients were treated either with freshly isolated or IL-2-stimulated NK-donor lymphocyte infusion (NK-DLI) after haploidentical SCT without any signs of GvHD when less than 25 × 103/kg NK cells were injected (29–31).